Cipla Shares Drop 5% After Lanreotide Production Halt

Cipla, a big pharma company, stopped making a key drug called Lanreotide for a short time.

This is because they need to fix some issues at their factory, as asked by US health regulators.

Lanreotide is very important for Cipla, especially in the US market.

Because of this news, Cipla's shares dropped by 5%.

Some experts think this is bad for Cipla's earnings, but others believe the shares have already dropped enough and might go up again.

Cipla is still a leader in the Indian pharma market and does well in selling medicines within India.